Obstructive Hypertrophic Cardiomyopathy Clinical Trials
3 recruiting trials for Obstructive Hypertrophic Cardiomyopathy. Eligibility criteria explained in plain English.
TrialFinderData lists 3 Obstructive Hypertrophic Cardiomyopathy clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.
Every phased trial in this set is Phase 3 (1 of the listed studies); the remaining records are observational or have no phase recorded on ClinicalTrials.gov.
Research is led by Bristol-Myers Squibb (2), Shandong Suncadia Medicine Co., Ltd. (1), among the most active sponsors registered for these trials.
The most frequently studied intervention is Mavacamten (drug, 2 trials), followed by HRS-1893 Tablets, HRS-1893 Placebo Tablets.
Track Obstructive Hypertrophic Cardiomyopathy trials
Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.
Recruiting Trials
Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.
A Phase III Trial of HRS-1893 in Patients With Obstructive Hypertrophic Cardiomyopathy
The study is being conducted to evaluate the efficacy and safety of HRS-1893 for obstructive hypertrophic cardiomyopathy.
Real-world Patient Reported Outcomes Among Patients Treated With Camzyos
This real-world study will assess changes in health status among participants with symptomatic obstructive hypertrophic cardiomyopathy who are treated with mavacamten in the real...
A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal...
This registry evaluates patient characteristics, real-world treatment patterns, and short- and long-term outcomes in a population of patients in the United States and Europe with...
Explore Other Conditions
Frequently Asked Questions
There are currently 3 clinical trials for Obstructive Hypertrophic Cardiomyopathy, with 3 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.
To join a clinical trial for Obstructive Hypertrophic Cardiomyopathy, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.
Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 1 Phase 3 trials for Obstructive Hypertrophic Cardiomyopathy, representing treatments closest to potential FDA approval.
Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.
Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.